Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (HK:2315) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a public company limited by shares in China, has announced a Board meeting scheduled for August 28, 2024. The agenda includes reviewing and approving the interim results for the first half of the year and discussing potential interim dividend payments. The announcement was made by Chairman and CEO Shen Yuelei on behalf of the Board, which consists of a mix of executive, non-executive, and independent directors.
For further insights into HK:2315 stock, check out TipRanks’ Stock Analysis page.